Phreesia Announces First Quarter Fiscal 2026 Results

ALL-REMOTE COMPANY/WILMINGTON, Del.–(BUSINESS WIRE)–Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the «Company») announced financial results today for the fiscal first quarter ended April 30, 2025.


«Our fiscal year 2026 is off to a strong start. I am grateful to our team for their continued commitment to our mission, vision and values. I believe our performance is a reflection of our team truly living our values,” said CEO and Co-Founder Chaim Indig.

Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company’s Q1 Fiscal 2026 Stakeholder Letter.

Fiscal First Quarter Ended April 30, 2025 Highlights

  • Total revenue was $115.9 million in the quarter, up 15% year-over-year.
  • Average number of healthcare services clients («AHSCs») was 4,411 in the quarter, up 9% year-over-year.
  • Total revenue per AHSC was $26,283 in the quarter, up 6% year-over-year. See «Key Metrics» below for additional information.
  • Net loss was $3.9 million in the quarter, as compared to net loss of $19.7 million in the same period in the prior year.
  • Adjusted EBITDA1 was $20.8 million in the quarter, as compared to $4.1 million in the same period in the prior year.
  • Net cash provided by operating activities was $14.9 million in the quarter, as compared to net cash used in operating activities of $0.7 million in the same period in the prior year.
  • Free cash flow2 was $7.5 million in the quarter, as compared to negative $6.2 million in the same period in the prior year.
  • Cash and cash equivalents as of April 30, 2025 was $90.9 million, up $6.7 million from January 31, 2025.

Fiscal 2026 Outlook

We are maintaining our revenue outlook for fiscal 2026. We expect revenue to be in the range of $472 million to $482 million. The revenue range provided for fiscal 2026 assumes no additional revenue from potential future acquisitions completed between now and January 31, 2026.

We are updating our Adjusted EBITDA outlook for fiscal 2026 to a range of $85 million to $90 million from a previous range of $78 million to $88 million. The Adjusted EBITDA range provided for fiscal 2026 assumes continued improvements in operating leverage across the Company through a focus on efficiency.

We are maintaining our expectation for AHSCs to reach approximately 4,500 in fiscal 2026. Additionally, we expect total revenue per AHSC in fiscal 2026 to increase from fiscal 2025.

We believe our $90.9 million in cash and cash equivalents as of April 30, 2025, along with cash generated in our normal operations, gives us sufficient flexibility to reach our fiscal 2026 outlook. Additionally, our available borrowing capacity under our credit facility with Capital One provides us with an additional source of capital to pursue future growth opportunities not incorporated into our fiscal 2026 outlook. As of April 30, 2025 we had no borrowings outstanding under our credit facility.

Non-GAAP3 Financial Measures

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP Net income (loss) due to the uncertainty and potential variability of other (income) expense, net and (benefit from) provision for income taxes, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see “Non-GAAP financial measures” below.

Available Information

We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Forward Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, margins, Adjusted EBITDA and cash flows; our ability to finance our plans to achieve our fiscal 2026 outlook with our current cash balance and cash generated in the normal course of business; and our outlook for fiscal 2026, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and total revenue per AHSC. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the competitive environment in which we operate; our ability to comply with the covenants in our credit agreement with Capital One; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; and difficulties in integrating our acquisitions and investments; and other general, market, political, economic and business conditions (including from the change in U.S. presidential administration, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East, India or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC”), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2025 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

Conference Call Information

We will hold a conference call on Wednesday May 28, 2025 at 8:30 a.m. Eastern Time to review our fiscal 2026 first quarter financial results. To participate in our live conference call and webcast, please dial (800) 715-9871 (or (646) 307-1963 for international participants) using conference code number 7404611 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Phreesia

Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes.

 

Phreesia, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

April 30, 2025

 

January 31, 2025

 

(Unaudited)

 

 

Assets

 

 

 

Current:

 

 

 

Cash and cash equivalents

$

90,871

 

 

$

84,220

 

Settlement assets

 

33,006

 

 

 

29,176

 

Accounts receivable, net of allowance for doubtful accounts of $1,811 and $1,468 as of April 30, 2025 and January 31, 2025, respectively

 

75,099

 

 

 

73,617

 

Deferred contract acquisition costs

 

414

 

 

 

401

 

Prepaid expenses and other current assets

 

16,019

 

 

 

15,871

 

Total current assets

 

215,409

 

 

 

203,285

 

Property and equipment, net of accumulated depreciation and amortization of $87,488 and $84,505 as of April 30, 2025 and January 31, 2025, respectively

 

23,492

 

 

 

23,651

 

Capitalized internal-use software, net of accumulated amortization of $59,013 and $55,991 as of April 30, 2025 and January 31, 2025, respectively

 

53,531

 

 

 

52,763

 

Operating lease right-of-use assets

 

1,262

 

 

 

1,477

 

Deferred contract acquisition costs

 

460

 

 

 

583

 

Intangible assets, net of accumulated amortization of $9,277 and $8,407 as of April 30, 2025 and January 31, 2025, respectively

 

27,273

 

 

 

28,143

 

Goodwill

 

75,845

 

 

 

75,845

 

Other assets

 

3,123

 

 

 

2,668

 

Total Assets

$

400,395

 

 

$

388,415

 

Liabilities and Stockholders’ Equity

 

 

 

Current:

 

 

 

Settlement obligations

$

33,006

 

 

$

29,176

 

Current portion of finance lease liabilities and other debt

 

8,348

 

 

 

8,043

 

Current portion of operating lease liabilities

 

957

 

 

 

964

 

Accounts payable

 

3,204

 

 

 

5,622

 

Accrued expenses

 

34,059

 

 

 

37,460

 

Deferred revenue

 

31,146

 

 

 

32,758

 

Total current liabilities

 

110,720

 

 

 

114,023

 

Long-term finance lease liabilities and other debt

 

6,162

 

 

 

8,150

 

Operating lease liabilities, non-current

 

401

 

 

 

646

 

Long-term deferred revenue

 

112

 

 

 

119

 

Long-term deferred tax liabilities

 

568

 

 

 

484

 

Other long-term liabilities

 

246

 

 

 

185

 

Total Liabilities

 

118,209

 

 

 

123,607

 

Commitments and contingencies

 

 

 

Stockholders’ Equity:

 

 

 

Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both April 30, 2025 and January 31, 2025; no shares issued or outstanding as of both April 30, 2025 and January 31, 2025

 

 

 

 

 

Common stock, $0.01 par value—500,000,000 shares authorized as of both April 30, 2025 and January 31, 2025; 60,814,930 and 60,083,444 shares issued as of April 30, 2025 and January 31, 2025, respectively

 

608

 

 

 

601

 

Additional paid-in capital

 

1,132,124

 

 

 

1,111,274

 

Accumulated deficit

 

(805,410

)

 

 

(801,496

)

Accumulated other comprehensive income (loss)

 

384

 

 

 

(51

)

Treasury stock, at cost, 1,355,169 shares as of both April 30, 2025 and January 31, 2025

 

(45,520

)

 

 

(45,520

)

Total Stockholders’ Equity

 

282,186

 

 

 

264,808

 

Total Liabilities and Stockholders’ Equity

$

400,395

 

 

$

388,415

 

 

Phreesia, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

 

 

Three months ended
April 30,

 

 

2025

 

 

 

2024

 

Revenue:

 

 

 

Subscription and related services

$

54,355

 

 

$

46,742

 

Payment processing fees

 

29,925

 

 

 

27,060

 

Network solutions

 

31,656

 

 

 

27,415

 

Total revenues

 

115,936

 

 

 

101,217

 

Expenses:

 

 

 

Cost of revenue (excluding depreciation and amortization)

 

16,637

 

 

 

15,723

 

Payment processing expense

 

21,428

 

 

 

18,297

 

Sales and marketing

 

26,043

 

 

 

32,011

 

Research and development

 

31,829

 

 

 

28,881

 

General and administrative

 

16,408

 

 

 

19,052

 

Depreciation

 

2,986

 

 

 

3,524

 

Amortization

 

3,892

 

 

 

3,149

 

Total expenses

 

119,223

 

 

 

120,637

 

Operating loss

 

(3,287

)

 

 

(19,420

)

Other income (expense), net

 

338

 

 

 

(31

)

Interest (expense) income, net

 

(230

)

 

 

239

 

Total other income, net

 

108

 

 

 

208

 

Loss before provision for income taxes

 

(3,179

)

 

 

(19,212

)

Provision for income taxes

 

(735

)

 

 

(510

)

Net loss

$

(3,914

)

 

$

(19,722

)

Net loss per share attributable to common stockholders, basic and diluted

$

(0.07

)

 

$

(0.35

)

Weighted-average common shares outstanding, basic and diluted

 

58,920,782

 

 

 

56,666,311

 

(1) Our potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

 

Phreesia, Inc.

Unaudited Consolidated Statements of Comprehensive Loss

(in thousands)

 

 

Three months ended
April 30,

 

 

2025

 

 

 

2024

 

Net loss

$

(3,914

)

 

$

(19,722

)

Other comprehensive income:

 

 

 

Net change in unrealized gains on cash flow hedges

 

407

 

 

 

 

Change in foreign currency translation adjustments

 

28

 

 

 

1

 

Other comprehensive income

 

435

 

 

 

1

 

Comprehensive loss

$

(3,479

)

 

$

(19,721

)

 

Phreesia, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

 

 

Three months ended
April 30,

 

 

2025

 

 

 

2024

 

Operating activities:

 

 

 

Net loss

$

(3,914

)

 

$

(19,722

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

Depreciation and amortization

 

6,878

 

 

 

6,673

 

Stock-based compensation expense

 

17,225

 

 

 

16,840

 

Amortization of deferred financing costs and debt discount

 

62

 

 

 

61

 

Cost of Phreesia hardware purchased by customers

 

436

 

 

 

343

 

Deferred contract acquisition costs amortization

 

110

 

 

 

192

 

Non-cash operating lease expense

 

215

 

 

 

173

 

Deferred taxes

 

85

 

 

 

63

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(1,490

)

 

 

(1,393

)

Prepaid expenses and other assets

 

(256

)

 

 

414

 

Accounts payable

 

(1,739

)

 

 

(2,936

)

Accrued expenses and other liabilities

 

(891

)

 

 

(1,155

)

Lease liabilities

 

(252

)

 

 

(219

)

Deferred revenue

 

(1,619

)

 

 

(55

)

Net cash provided by (used in) operating activities

 

14,850

 

 

 

(721

)

Investing activities:

 

 

 

Capitalized internal-use software

 

(3,888

)

 

 

(4,570

)

Purchases of property and equipment

 

(3,504

)

 

 

(876

)

Net cash used in investing activities

 

(7,392

)

 

 

(5,446

)

Financing activities:

 

 

 

Proceeds from issuance of common stock upon exercise of stock options

 

128

 

 

 

347

 

Proceeds from employee stock purchase plan

 

768

 

 

 

913

 

Finance lease payments

 

(1,376

)

 

 

(1,280

)

Principal payments on financing agreements

 

(320

)

 

 

(289

)

Debt issuance costs and loan facility fee payments

 

(38

)

 

 

(152

)

Financing payments of acquisition-related liabilities

 

 

 

 

(1,364

)

Net cash used in financing activities

 

(838

)

 

 

(1,825

)

Effect of exchange rate changes on cash and cash equivalents

 

31

 

 

 

(1

)

Net increase (decrease) in cash and cash equivalents

 

6,651

 

 

 

(7,993

)

Cash and cash equivalents – beginning of period

 

84,220

 

 

 

87,520

 

Cash and cash equivalents – end of period

$

90,871

 

 

$

79,527

 

 

 

 

 

 

 

 

 

Supplemental information of non-cash investing and financing information:

 

 

 

Right of use assets acquired in exchange for operating lease liabilities

$

 

 

$

764

 

Property and equipment acquisitions through finance leases

$

 

 

$

6,529

 

Purchase of property and equipment and capitalized software included in current liabilities

$

1,117

 

 

$

2,440

 

Capitalized stock-based compensation

$

332

 

 

$

348

 

Issuance of stock to settle liabilities for stock-based compensation

$

6,508

 

 

$

6,177

 

Cash paid for:

 

 

 

Interest

$

324

 

 

$

483

 

Income taxes

$

551

 

 

$

1,593

 

Non-GAAP Financial Measures

This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income or loss before interest expense (income), net, provision for income taxes, depreciation and amortization, and before stock-based compensation expense and other (income) expense, net.

We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other (income) expense, net and (benefit from) provision for income taxes, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

  • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
  • Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; or (4) interest expense (income), net; and
  • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, for each of the periods indicated:

 

Phreesia, Inc.

Adjusted EBITDA

 

 

Three months ended

April 30,

(in thousands, unaudited)

 

2025

 

 

 

2024

 

Net loss

$

(3,914

)

 

$

(19,722

)

Interest expense (income), net

 

230

 

 

 

(239

)

Provision for income taxes

 

735

 

 

 

510

 

Depreciation and amortization

 

6,878

 

 

 

6,673

 

Stock-based compensation expense

 

17,225

 

 

 

16,840

 

Other (income) expense, net

 

(338

)

 

 

31

 

Adjusted EBITDA

$

20,816

 

 

$

4,093

 

We calculate free cash flow as net cash provided by (used in) operating activities less capitalized internal-use software development costs and purchases of property and equipment.

Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic investments, partnerships and acquisitions and strengthening our financial position.

The following table presents a reconciliation of free cash flow from net cash provided by (used in) operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

 

Phreesia, Inc.

Free cash flow

 

 

Three months ended

April 30,

(in thousands, unaudited)

 

2025

 

 

 

2024

 

Net cash provided by (used in) operating activities

$

14,850

 

 

$

(721

)

Less:

 

 

 

Capitalized internal-use software

 

(3,888

)

 

 

(4,570

)

Purchases of property and equipment

 

(3,504

)

 

 

(876

)

Free cash flow

$

7,458

 

 

$

(6,167

)

 

Phreesia, Inc.

Reconciliation of GAAP and Adjusted Operating Expenses

 

 

Three months ended

April 30,

(in thousands, unaudited)

 

2025

 

 

2024

GAAP operating expenses

 

 

 

General and administrative

$

16,408

 

$

19,052

Sales and marketing

 

26,043

 

 

32,011

Research and development

 

31,829

 

 

28,881

Cost of revenue (excluding depreciation and amortization)

 

16,637

 

 

15,723

 

$

90,917

 

$

95,667

Stock compensation included in GAAP operating expenses

 

 

 

General and administrative

$

6,573

 

$

6,209

Sales and marketing

 

5,174

 

 

5,766

Research and development

 

4,393

 

 

3,627

Cost of revenue (excluding depreciation and amortization)

 

1,085

 

 

1,238

 

$

17,225

 

$

16,840

Adjusted operating expenses

 

 

 

General and administrative

$

9,835

 

$

12,843

Sales and marketing

 

20,869

 

 

26,245

Research and development

 

27,436

 

 

25,254

Cost of revenue (excluding depreciation and amortization)

 

15,552

 

 

14,485

 

$

73,692

 

$

78,827

 

Phreesia, Inc.

Key Metrics

(Unaudited)

 

 

Three months ended
April 30,

 

 

2025

 

 

2024

Key Metrics:

 

 

 

Average number of healthcare services clients («AHSCs»)

 

4,411

 

 

4,065

Total revenue per AHSC

$

26,283

 

$

24,900

Contacts

Investor Relations Contact:

Balaji Gandhi

Phreesia, Inc.

investors@phreesia.com
(929) 506-4950

Media Contact:

Nicole Gist

Phreesia, Inc.

nicole.gist@phreesia.com
(407) 760-6274

Read full story here

Artículos Relacionados